Eledon Pharmaceuticals
ELDN
50 hedge funds and large institutions have $82.2M invested in Eledon Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 9 closing their positions.
144% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 9
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
18% more capital invested
Capital invested by funds: $70M → $82.2M (+$12.3M)
4% more funds holding
Funds holding: 48 → 50 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$2.93M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.53M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$873K |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$753K |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$646K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$3.45M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.65M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$1.13M |
| 4 |
SCM
Sio Capital Management
New York
|
-$930K |
| 5 |
DA
DSC Advisors
Chicago,
Illinois
|
-$791K |
ELDN Hedge Fund Activity: Q2 2015 in Review
50 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2015, worth a combined $82.2M — up 18% from $70M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ELDN positions and 9 closed out — a net gain of 2 holders — while 22 added to existing stakes and 9 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $2.93M. The largest seller was Discovery Capital Management, cutting an estimated $3.45M.
- 50 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2015, up from 48 in Q1 2015.
- Funds reported $82.2M of Eledon Pharmaceuticals stock for Q2 2015, up 18% quarter-over-quarter.
- 11 funds opened new Eledon Pharmaceuticals positions in Q2 2015 and 9 closed out, a net change of +2 holders.
- The largest Eledon Pharmaceuticals buyer in Q2 2015 was Bank of New York Mellon, an estimated $2.93M added.
- The largest Eledon Pharmaceuticals seller in Q2 2015 was Discovery Capital Management, an estimated $3.45M sold.
Based on aggregated 13F filings for Q2 2015.